Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Completed · Phase 2

Conditions studied: Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms

In brief

The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).

Key facts

Study ID

NCT00038376

Run by

M.D. Anderson Cancer Center

People needed

56

Starts

1990-05-08

Expected to finish

2005-06-30

Last updated by the study team

2018-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologic proof of incurable T-cell malignancy or Hodgkin's disease, and not eligible for existing/higher priority protocols. Patients with Hodgkin's disease will be eligible only if they have failed at least a MOPP-like and ABVD-like regimen.
• Patients should not have received chemotherapy, immunotherapy, hormonal therapy, or radiation therapy within three weeks of entry into the study and must have recovered from acute toxic effects of prior therapy.
• Patients must have a life expectancy of at least 12 weeks and a performance status of less than or equal to 2 (Zubrod scale: Appendix A).
• Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with policies of the hospital. The only approved consent form is appended to this protocol.
• Patients must have measurable or evaluable disease.
• Patients must be greater than or equal to 18 years old.
• Patients may receive no other concurrent chemotherapy, immunotherapy, or radiotherapy.
• Patients should have adequate hepatic function with bilirubin of less than or equal to 2.0 mg%, and SGPT of less than or equal to 4 times the upper limits of normal.
• Patients should have adequate renal function (defined as serum creatinine of less than or equal to 2.0 mg%).
• Patients should have serum triglyceride level less than or equal to 2.5 times the upper limits of normal.
• Patients may not have serious intercurrent medical illness.
• Patients of child bearing potential must be practicing adequate contraception.
• Patients will be eligible regardless of the extent of prior chemotherapy.

You may not qualify if…

• Pediatric Patients under 18 years old.

Where it is running

• M. D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.